Neuberger Berman Group
ADMS

Neuberger Berman Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Neuberger Berman Group’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-27,000
Closed -$915K – 1771
2017
Q4 		$915K Buy
+27,000
New +$754K ﹤0.01% 1243

Other funds holding ADMS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group's ADMS Position: Q1 2018 in Review

Neuberger Berman Group sold out of Adamas Pharmaceuticals (ADMS) in Q1 2018, closing a stake of 27,000 shares — an estimated $915K sold.

Neuberger Berman Group first reported a position in ADMS in Q4 2017 and held it in 1 quarter. The position peaked at $915K in Q4 2017. 118 funds tracked by Wall St. Rank hold ADMS as of Q1 2018.

  • Neuberger Berman Group reported no remaining Adamas Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 27,000 Adamas Pharmaceuticals shares in Q1 2018, an estimated $915K.
  • Neuberger Berman Group first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Neuberger Berman Group's Adamas Pharmaceuticals position peaked at $915K in Q4 2017.
  • 118 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2018.

Based on Neuberger Berman Group's 13F filing for Q1 2018, filed 8 May 2018.